Investigating dynamics of carbapenemases in bacteria isolated from human clinical samples

Carbapenem antibiotics are often considered the “last line of defense” for treating severe bacterial infections. However, an increasing number of bacteria have developed enzymes called carbapenemases that break down these drugs, rendering them ineffective. This research aims to investigate how these carbapenemase-producing bacteria emerge, spread, and persist in human clinical settings. By combining laboratory detection, genetic sequencing, and epidemiological analysis, the study will track the movement of resistance genes within and between bacterial species.

The findings will help improve patient outcomes by enabling earlier detection of resistant infections and supporting clinicians in selecting effective treatments. By identifying the genetic mechanisms that drive resistance, the study will strengthen antimicrobial stewardship, guiding rational antibiotic use and reducing unnecessary exposure to carbapenems. Understanding how resistance genes spread in hospitals and communities will inform public health practice, supporting targeted infection-control measures and real-time surveillance. Ultimately, this work will strengthen health systems by generating evidence for integrated laboratory–epidemiology networks and national AMR response strategies—helping preserve the effectiveness of life-saving antibiotics for future generations.